NEW STRATEGIES FOR THE TREATMENT OF MOOD DISORDERS: THE TRIPLE REUPTAKE INHIBITORS

Size: px

Start display at page:

Download "NEW STRATEGIES FOR THE TREATMENT OF MOOD DISORDERS: THE TRIPLE REUPTAKE INHIBITORS"

Esther Fowler
5 years ago
Views:

1 Send Orders for Reprints to 234 Neurobiology of Mood Disorders, 2013, NEW STRATEGIES FOR THE TREATMENT OF MOOD DISORDERS: THE TRIPLE REUPTAKE INHIBITORS GAËL QUESSEVEUR, BRUNO GUIARD * Faculty of Pharmacy, University Paris South IV, Paris, France Abstract: norepinephrine and dopamine extracellular levels in the brain may produce greater antidepressant effects than single- or dual-acting agents. This hypothesis is mainly based on the observations that drugs stimulating dopaminergic neurotransmission produce antidepressant effects or attenuate some side effects observed with selective serotonin reuptake inhibitors. Although preclinical data been tested mainly after acute administration. However, given the functional and reciprocal interactions between monoaminergic neurons, it is conceivable that counter-productive effects like activity is based exclusively on the forced swim and tail suspension tests in naïve animals which do not reproduce the complex biological and psychological changes associated with present chapter synthesizes the preclinical and clinical data emphasizing the interest of increasing dopaminergic activity with the other two monoamines in the treatment of major depression and related symptoms such as pain. Keywords: norepinephrine (NET) and dopamine (DAT) transporters, depression, antidepressant drugs, triple 1. INTRODUCTION monoaminergic neurotransmission in various brain areas including the frontal cortex, hippocampus, and pleasure result from an attenuation of dopaminergic In this context, it is not surprising that most antidepressants approved, act by enhancing extracellular * Address correspondence to Bruno P. Guiard: bruno.guiard@u-psud.fr CHAPTER 10 Disclosure: Part of information included in this chapter has been previously published as B.P. Guiard (2011). A New Class of Antidepressant Drugs in the treatment of Psychiatric Disorders: The Triple Reuptake Inhibitors, Psychiatric Disorders Trends and Developments, Dr. Toru Uehara (Ed.), ISBN: , InTech Bruno P Guiard and Eliyahu Dremencov (Eds) All rights reserved Bentham Science Publishers

2 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 235 A growing body of literature suggests that antidepressants with more than one mechanism of action the classic approach is to switch medications, ideally using an antidepressant with an additional Converging lines of evidence indicate that drugs enhancing dopaminergic neurotransmission can to achieve an antidepressant action by enhancing DA neurotransmission. This is supported by several reports of the augmenting action of the D2 receptor agonists such as pramipexole in treatment-resistant Together, these clinical considerations, have given rise to a new class of antidepressants that attenuating some side effects observed in response to traditional antidepressants. It is also possible that 2. PRECLINICAL PROPERTIES OF TRIPLE REUPTAKE INHIBITORS A number of compounds with the ability to bind and block all three monoamine transporters have been developed with the hope to produce greater symptomatic relief than single- or dual-acting agents. in vitro and in vivo preclinical data with

3 236 Neurobiology of Mood Disorders Quesseveur and Guiard 2.1. IN VITRO In vitro depending on their relative potencies at binding and/or inhibiting the three monoaminergic their ability to block preferentially one transporter. It is thus possible to have a perfectly balanced in vitro and in vivo data Binding properties of TRIs In vitro 1. Despite distinct TABLE 1 TRIs In vitro binding (Ki or Kd in nm) SERT NET DAT References DOV a [49] DOV a [105] Bicifadine a [47] PRC200-SS b [39] PRC050 b [48] PRC025 b [48] JNJ a [46] TP1 a [92] Table 1: a of radioligand binding). b In vitro functional activity of TRIs assessed from synaptosomal preparation methods to assess the in vitro potency of reuptake inhibitors and to predict their selectivity towards

4 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders (Table 2) reported with monoaminergic systems. In particular, it has been shown that the clearance of NE TP1, it blocks the reuptake of all three monoamines with the same potency (Table 2) despite its (Table 1) cells. If these unexpected observations result from methodological issues in relation with the use of in vitro transfected cells, one would expect a higher degree of correlation in vivo. TABLE 2 In vitro uptake In vivo uptake References TRI (synaptosomes) (intracerebral microdialysis) (IC50, Kd or Ki in nm) SERT NET DAT 5-HT NE DA DOV a [31,106, 107] DOV a [49] Bicifadine a [45,47] PRC200-SS c [39] PRC050 c [48] PRC025 c [48] JNJ a [46] TP1 a [44] JZAD-IV-22 a [31] Table 2: In vitro and in vivo functional activity of triple reuptake inhibitors (TRIs) from synaptosomes and intracerebral microdialysis. a b,c Determined In vivo functional activity of TRIs assessed by intracerebral microdialysis studies In vivo transporters and, on the model used naïve vs different (Table 2)

5 238 Neurobiology of Mood Disorders Quesseveur and Guiard extracellular levels of the three monoamines in the medial prefrontal cortex (mpfc) and the Nucleus in vitro levels is related to a weak expression of DAT in the rodent mpfc (in comparison to human). Secondly, 2C receptor characterized by 2C receptor also inhibits DA release in the nigrostrial and emphasizes the fact that even in vivo that in vivo, in vitro property either in term of have attenuated the expected increase in DA in the synaptic cleft. and DAT has been provided. A preferential increase in DA with both compounds in the cortex and in vitro bicifadine displayed a better in vitro Antidepressant-like activity of TRIs abuse liability, cannot be predicted accurately based on in vitro or in vivo alone. Therefore, the use of behavioral screening approach to supplement the neurochemical data for in vivo In naïve animals agents are the forced swimming and the tail suspension tests ( and, respectively). Behavioral increasing the time of mobility and/or by reducing the time of immobility in the or the (Table 3 3 attenuate the increase in extracellular levels of DA. The reasons of such discrepancy remain obscure and should draw attention for future investigations.

6 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 239 increased the time of mobility in these various studies, through a psychostimulant effect. In various does not appear to be from false-positive results In animal models of depression An important drawback in the development of antidepressants is due to the fact that the new compounds are tested after acute administration in naïve non-depressed animals. Their chronic use in animal models is more appropriate and provide more informative results to determine whether or not a new pharmacological agents worth being tested in clinical trials. A recent study in bulbectomized TABLE 3 TRIs Doses, routes Tests Mobility (% of baseline increase) Immobility (% of baseline decrease) References (rats) (rats) (active enantiomere of (rats)

7 (active enantiomere of (rats) D-142 (Subchronic) (rats) (Subchronic) (rats) - 3-aryl-3-azolylpropan- 1-amines 4-(3,4-dichlorophenyl)- N-methyl-1,2,3,4- tetrahydronaphthalenyl 240 Neurobiology of Mood Disorders Quesseveur and Guiard

8 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 241 N-methyl-1-(1-phenylcyclohexyl)methanamine (compound #1) N-methyl-1-(1-phenylcyclohexyl)methanamine (compound #31) Aryl pyrrole TP1 TP1 Benzhydryltetrahydro-2Hpyran-3 yl)amino)methyl) phenol (rats) Table 3: Antidepressant-like activity of triple reuptake inhibitors (TRIs) assessed in the forced swimming and tail suspension tests. between studies, in term of intensity of effect, are not necessarily relevant. : Not Determined Impact of TRIs on neurogenesis Beyond the monoamine hypothesis, it has been suggested that neural adaptive mechanisms may olfactory bulbectomy, showing that various components of the limbic circuitry may exhibit alterations also suggest that catecholamines (NE and DA) also stimulate neurogenesis. For example, in addition have been shown to produce antidepressant-like effects in behavioral models), it was demonstrated that sustained administration of the reuptake inhibitors venlafaxine and imipramine, increased BDNF system activates different downstream cascades that are both able to increase the transcription of BDNF.

9 242 Neurobiology of Mood Disorders Quesseveur and Guiard Whether or not this effect resulted from an additive effect on noradrenergic and serotonergic systems is regulation of BDNF expression and neurogenesis. However, dopaminergic denervation in animals stimulation of DA receptors with selective D 2 agonists has recently been shown to enhance neurogenesis in vivo experiments, it has been shown that the Cytokine Ciliary Neurotrophic Factor (CNTF), abundant in astrocytes close to dopaminergic terminals, constitutes an endogenous regulatory component of D 2 -receptor-dependent neurogenesis in situ hybridization, an initial study each of the monoamine reuptake sites remains unknown. Further studies are truly necessary to dissect the contribution of each monoamine uptake target on the regulation of BDNF or others neurotrophic factors gene expression. It is possible that the stimulation of the expression of various neurotrophic DA transmission, might contribute to shorten the delay of action of traditional antidepressants drugs. prominent evidence comes from the observation that decreased levels of BDNF could contribute can be expected to determine the real impact of neurogenesis in treatment response induced by monoaminergic antidepressants, although methodological limitations impede the parallel between clinical and preclinical observations Impact of TRIs on astro-glial cells Interestingly, glia and more particularly astrocytes are now recognized as partners with neurons in many aspect of brain function such as neuronal plasticity. It is thus conceivable that these cells are aminodipate-induced decrease in the density of astrocytes in the prefrontal cortex (PFCx) of adult mechanism of antidepressant on glia is still not clear, current researches focus on the possibility that this cell population constitutes a major source of neurotrophic factors available for the proliferation, maturation and differentiation of progenitor cells. Accordingly, in vitro studies demonstrated that

10 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 243 and/or NE may stimulate the production of neurotrophic/growth factors. This observation has been more robust effects than single- or dual-acting agents. 3. CLINICAL EVIDENCE FOR ANTIDEPRESSANT ACTIVITY OF TRIPLE REUPTAKE INHIBITORS Bupropion is an antidepressant with novel neurotransmitter properties (NE and DA reuptake inhibitor) prospective open-label studies were designed to evaluate this strategy in depressed patients who In major depression a core symptom of depression that is presumed to be related to a hypodopaminergia. Despite these Other symptoms of MD triggered by TRIs: pain perception somatic symptoms, including various types of pain such as headaches, stomach pain, back pain, and

11 244 Neurobiology of Mood Disorders Quesseveur and Guiard Indeed, pain is a bi-directional process of ascending and descending neuronal pathways involving now considered as an essential component of the therapeutic strategy for treatment of many types by a recent preclinical study characterizing the antinociceptive effects of bicifadine in acute, persistent mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of pain, including acute postsurgical pain and chronic low back pain, and is being evaluated for painful diabetic neuropathy (clinical trial.gov) Safety and Tolerability of TRIs escalating, placebo-controlled, double blind, phase 1a trial, no adverse effects were observed at side effects were noted, although diarrhea, vomiting and nausea were observed. This is also the case effect was probably related to blockade of the NE transporter, which in turn activates noradrenergic disorders (dyskinesia and headache), gastrointestinal tract disorders (nausea and constipation), and not observed with amitifadine raising the possibility that the intensity of binding and/or inactivation of the distinct monoaminergic transporters are important parameters to anticipate adverse event

12 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders CONCLUSION single- or dual-acting agents mainly due to the dopaminergic component. Firstly, it is believed that e.g., sexual dysfunctions) commonly DA may favor the activity of the serotonergic system. Indeed, anatomical and functional interactions of D 2 administration of the D 2 greater antidepressant-(like) activity and neurogenic process has yet to be determined. REFERENCES Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur

13 246 Neurobiology of Mood Disorders Quesseveur and Guiard medications from treatment initiation for major depressive disorder: a double-blind randomized study. 11 Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart Tremblay P, Blier P. Catecholaminergic strategies for the treatment of major depression. Curr

14 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and

15 248 Neurobiology of Mood Disorders Quesseveur and Guiard effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. BE, Carruthers NI. In-vitro and in-vivo

16 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 249 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and

17 250 Neurobiology of Mood Disorders Quesseveur and Guiard neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience

18 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 251 increase glial cell line-derived neurotrophic factor production through monoamine-independent

19 252 Neurobiology of Mood Disorders Quesseveur and Guiard of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor CNS :

20 New Strategies for the Treatment of Mood Disorders: The Triple Reuptake Inhibitors Neurobiology of Mood Disorders 253 derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-

pharmaceuticals ISSN

Pharmaceuticals 2011, 4, 285-342; doi:10.3390/ph4020285 Review OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Monoaminergic Antidepressants in the Relief of Pain: Potential